Relief Therapeutics Holding AG - Asset Resilience Ratio

Latest as of December 2023: 0.01%

Relief Therapeutics Holding AG (RLF) has an Asset Resilience Ratio of 0.01% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CHF9.00K

≈ $11.38K USD Cash + Short-term Investments

Total Assets

CHF76.39 Million

≈ $96.58 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2006–2023)

This chart shows how Relief Therapeutics Holding AG's Asset Resilience Ratio has changed over time. Check Relief Therapeutics Holding AG (RLF) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Relief Therapeutics Holding AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Relief Therapeutics Holding AG (RLF) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF0.00	0%
Short-term Investments	CHF9.00K	0.01%
Total Liquid Assets	CHF9.00K	0.01%

Asset Resilience Insights

Limited Liquidity: Relief Therapeutics Holding AG maintains only 0.01% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Relief Therapeutics Holding AG Industry Peers by Asset Resilience Ratio

Compare Relief Therapeutics Holding AG's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Syndax Pharmaceuticals Inc NASDAQ:SNDX	Biotechnology	46.79%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	63.47%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Relief Therapeutics Holding AG (2006–2023)

The table below shows the annual Asset Resilience Ratio data for Relief Therapeutics Holding AG.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	0.01%	CHF9.00K ≈ $11.38K	CHF76.39 Million ≈ $96.58 Million	0.00pp
2022-12-31	0.01%	CHF28.00K ≈ $35.40K	CHF188.80 Million ≈ $238.69 Million	--
2021-12-31	0.00%	CHF0.00 ≈ $0.00	CHF251.62 Million ≈ $318.11 Million	--
2020-12-31	0.24%	CHF185.00K ≈ $233.89K	CHF78.05 Million ≈ $98.67 Million	+0.18pp
2013-12-31	0.06%	CHF25.73K ≈ $32.54K	CHF45.98 Million ≈ $58.13 Million	-18.38pp
2006-12-31	18.43%	CHF14.15 Million ≈ $17.89 Million	CHF76.76 Million ≈ $97.05 Million	--

pp = percentage points

About Relief Therapeutics Holding AG

SW:RLF Switzerland Biotechnology

Market Cap

$45.93 Million

CHF36.33 Million CHF

Market Cap Rank

#23041 Global

#204 in Switzerland

Share Price

CHF2.89

Change (1 day)

+0.87%

52-Week Range

CHF2.45 - CHF3.66

All Time High

CHF280.00